Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Is the commercialization of European academic R&D weak?-A critical assessment of a dominant belief and associated policy responses

In English

Författare

Summary, in English

There is a widespread belief that EU underperforms in the commercialization of publicly funded research and that the appropriate policy response is to transfer the ownership of intellectual property rights to Universities. This paper assesses the validity of these twin beliefs. In addressing the first, we limit ourselves to Sweden which still retains its "Teacher's Exemption" model. In spite of confident statements made in the literature and by Government, we provide evidence to the contrary, i.e. that Swedish academia performs well in terms of commercialization. We also have doubts about the usefulness of the medicine prescribed to cure the alleged problem. Largely drawing on US literature, we argue that the medicine risks harming strong university-industry networks, biasing technical change, reducing entrepreneurial activity and generating costs to Universities which may be detrimental to technology transfer. In conclusion, we seriously question the validity of both beliefs. (C) 2013 Elsevier B.V. All rights reserved.

Avdelning/ar

Publiceringsår

2013

Språk

Engelska

Sidor

874-885

Publikation/Tidskrift/Serie

Research Policy

Volym

42

Issue

4

Dokumenttyp

Artikel i tidskrift

Förlag

Elsevier

Ämne

  • Social Sciences Interdisciplinary

Nyckelord

  • Dominant belief
  • Academic research
  • Commercialization
  • Technology
  • transfer
  • Sweden

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 0048-7333